Medeor Therapeutics Stock

medeortx.comHealthcare / BioTech & PharmaFounded: 2012Funding to Date: $67.55MM

Developer of cellular immunotherapies designed to improve outcomes in organ transplant recipients. The company's cellular immunotherapies consist of approaches to organ transplant immune tolerance and immuno-oncology, enabling healthcare providers to preserve or improve transplant kidney function and prevent graft rejection better than currently available immunosuppression (anti-rejection) drugs.

Register To Buy and Sell Shares

For more details on financing and valuation for Medeor Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Medeor Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Medeor Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Matthew Plunkett Ph.D
Chief Financial and Business Officer
Steven Deitcher MD
Co-Founder, Chief Executive Officer, President and Board Member
Iqbal Husain Ph.D
Senior Vice President, Program Management
Darin Weber Ph.D
Senior Vice President, Regulatory Affairs & Quality
D. Scott Batty MD
Chief Medical Officer
Samuel Strober MD
Scientific Founder
Elizabeth Read MD
Senior Vice President, Product Development
Michael Zdanowski
Vice President, Biopharmaceutical Operations

Board Members

Frank Kung Ph.D
Vivo Capital
Peter Kolchinsky Ph.D
RA Capital Management
Wei Li Ph.D
WuXi Healthcare Ventures
Anand Mehra MD
Sofinnova Investments
Steven Deitcher MD

Frequently Asked Questions About Medeor Therapeutics’ Stock

Can you buy Medeor Therapeutics’ stock?
Medeor Therapeutics is not publicly traded on NYSE or NASDAQ in the U.S. To buy Medeor Therapeutics’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell Medeor Therapeutics’ stock?
Yes, you can sell stock of a private company like Medeor Therapeutics. Forge can help you sell your Medeor Therapeutics stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is Medeor Therapeutics’ stock price?
Medeor Therapeutics is a privately held company and therefore does not have a public stock price. However, you may access Medeor Therapeutics’ private market stock price with Forge Data.
What is Medeor Therapeutics’ stock ticker symbol?
Medeor Therapeutics does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.
Updated on: May 17, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.